Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...
After a surprise failure in advanced liver cancer, Merck & Co. and Eisai are hoping new data can make their Keytruda-Lenvima combination a standard of care in intermediate-stage disease. | After a ...
Merck’s (NYSE:MRK) anti-PD-1 therapy Keytruda as part of a combination regimen with Eisai’s (OTCPK:ESALF) (OTCPK:ESAIY) ...
Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced ...
Patients with intermediate-stage liver cancer may benefit from receiving a Lenvima-Keytruda combination with transarterial ...
The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...
Merck's bumpy six-year relationship with Eisai's anti-cancer medication Lenvima landed on somewhat better footing in Spain ...
Eisai and Merck & Co have reported positive data from the LEAP-012 trial for their combination of Lenvima (lenvatinib) and ...
MedPage Today on MSN5d
Another Possible Treatment Option for Intermediate-Stage Liver CancerMedian PFS increased from 10 months with TACE to 14.6 months with the addition of lenvatinib (Lenvima) and pembrolizumab ...
Intermediate-stage hepatocellular carcinoma remains a challenge to treat. The new findings may lead to a new treatment ...
Discover they major updates in oncology from the 2024 ESMO Congress, including featured breakthroughs from the leading ...
AstraZeneca’s Phase 3 study in bladder cancer, showed that giving Imfinzi — before and after surgery — cut the risk of death.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback